GL-II-73

GL-II-73
Identifiers
IUPAC name
  • (4R)-8-ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-benzo[f]imidazo[1,5-a] [1,4]diazepine-3-carboxamide
PubChem CID
Chemical and physical data
FormulaC23H19FN4O
Molar mass386.430 g·mol−1
3D model (JSmol)
SMILES
  • CN(C)C(=O)c4ncn2c4[C@@H](C)N=C(c1cc(C#C)ccc12)c3ccccc3F
InChI
  • InChI=1S/C23H19FN4O/c1-5-15-10-11-19-17(12-15)20(16-8-6-7-9-18(16)24)26-14(2)22-21(23(29)27(3)4)25-13-28(19)22/h1,6-14H,2-4H3/t14-/m1/s1
  • Key:LNPOWXXHIUMIKI-CQSZACIVSA-N

GL-II-73 (GL-ii-073) is a benzodiazepine derivative related in chemical structure to compounds such as midazolam, adinazolam and the active metabolite of rilmazafone. It is described as an α5 preferring positive allosteric modulator of the benzodiazepine site of GABAA receptors, with weaker activity at α2 and α3 and no significant affinity for the α1 subtype. In animal tests it was found to produce effects consistent with antidepressant, anxiolytic and nootropic actions.[1][2][3][4]

See also

References

  1. ↑ CA 3016491, Cook JM, Li G, Poe M, Savic M, Sibille E, "Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists.", published 21 September 2017, assigned to Centre for Addiction and Mental Health, Faculty Of Pharmacy, University of Belgrade and UWM Res Foundation Inc
  2. ↑ Prevot TD, Li G, Vidojevic A, Misquitta KA, Fee C, Santrac A, et al. (January 2018). "Potential combined pro-cognitive, anxiolytic and antidepressant properties of novel GABAA receptor positive modulators with preferential efficacy at the α5-subunit" (PDF). bioRxiv: 332908. doi:10.1101/332908. S2CID 90987308.
  3. ↑ Prevot TD, Li G, Vidojevic A, Misquitta KA, Fee C, Santrac A, Knutson DE, Stephen MR, Kodali R, Zahn NM, Arnold LA, Scholze P, Fisher JL, Marković BD, Banasr M, Cook JM, Savic M, Sibille E (April 2019). "Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles". Molecular Neuropsychiatry. 5 (2): 84–97. doi:10.1159/000496086. PMC 6528097. PMID 31192221.
  4. ↑ Sibille E (February 2019). "Brain Inhibitory GABAergic Function and Cognitive Deficits: Mechanisms and Therapeutic Targeting" (PDF). Presentation for AAAS.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.